cefalexin monohydrate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
cefalexin monohydrate: clinical details
Prescribing considerations
- Confirm that infection is bacterial and likely to involve susceptible organisms; review microbiology results when available.
- Clarify previous cephalosporin, penicillin and other beta-lactam reactions.
- Consider renal function, age, neurological disease and concurrent nephrotoxic medicines.
- Investigate significant diarrhoea during or after treatment for antibiotic-associated colitis.
- Review prolonged use for superinfection with non-susceptible organisms.
Contraindications and cautions
- Known hypersensitivity to cefalexin, another cephalosporin or a product excipient.
- Use particular caution with previous immediate or severe beta-lactam hypersensitivity.
- Marked renal impairment increases accumulation and cephalosporin-associated neurotoxicity risk.
- Check formulation-specific excipients where sugar, sorbitol, sodium benzoate, lactose or colouring agents are clinically relevant.
Monitoring
- Renal function where impairment, older age or nephrotoxic co-treatment makes accumulation more likely.
- Clinical response and available culture or susceptibility results.
- New rash, anaphylaxis, severe diarrhoea, superinfection or neurological symptoms.
- Interpret direct Coombs testing and some urine glucose methods with awareness of possible interference.
Clinical pharmacology
An acid-stable, bactericidal first-generation cephalosporin that inhibits bacterial cell-wall synthesis. It is rapidly absorbed orally and eliminated mainly unchanged through the kidneys; renal impairment prolongs exposure.
Formulation and product differences
- Selected products include hard capsules, scored tablets and powders or granules requiring reconstitution as oral suspension.
- The selected tablet score facilitates swallowing and does not produce equal portions.
- Reconstituted suspension storage conditions and discard dates vary by product.
- Liquid and capsule excipients differ between products.
cefalexin monohydrate preparations and strengths
Capsule
Route: Oral
Strengths: 250 mg, 500 mg
Oral suspension
Route: Oral
Strengths: 125 mg/5 mL, 250 mg/5 mL
cefalexin monohydrate interactions
Tell the prescriber or pharmacist about all medicines and supplements. Relevant interactions include:
Probenecid
May increase or prolong cefalexin exposure by reducing its renal excretion.
Metformin
Cefalexin can increase metformin exposure. The clinical importance is uncertain, but review may be appropriate.
Aminoglycosides, other cephalosporins or potent diuretics
Concurrent use may increase kidney toxicity risk, particularly in susceptible patients.
Zinc-containing supplements
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.